Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics
Eli Lilly’s experimental eloralintide-Mounjaro combination produced average weight loss of up to 23% in people with diabetes over 48 weeks. The result gives Lilly another late-stage obesity-treatment asset as it competes with Novo Nordisk in a rapidly expanding market.
STOCK PHOTO · MAURÍCIO MASCAROParticipants receiving the highest dose lost an average of 54 pounds over 48 weeks, according to Bloomberg. Their A1C declined 2.9 percentage points from a baseline of 8.1%, and as many as three-quarters reached normal blood-sugar levels.
The combination pairs eloralintide, Lilly’s experimental obesity drug, with Mounjaro, its tirzepatide treatment for diabetes and obesity. The reported result adds to Lilly’s existing position in metabolic medicines and changes the competitive comparison with Novo Nordisk from single-drug performance toward combination regimens.
For Lilly, the commercial mechanism would run through demand for Mounjaro alongside a potential new eloralintide franchise. The reported weight-loss and glucose-control figures are from people with diabetes, so the read-through depends on how the combination performs across broader patient groups and in later-stage testing.
The report describes experimental results rather than an approved combination. Questions remain around durability, safety, dosing, regulatory requirements and whether the reported efficacy translates into a commercially viable treatment. The next evidence should come from additional clinical data and Lilly’s regulatory or development updates on eloralintide.
LLY’s eloralintide-Mounjaro combination delivered up to 23% average weight loss and a 2.9-point A1C decline in diabetics.
The result expands Lilly’s potential obesity franchise beyond Mounjaro, with the reported 23% weight loss and 2.9-point A1C reduction providing a concrete efficacy hook. Lilly already generated $65.2B of FY2025 revenue and a 31.7% net margin, so a successful combination could build on an established commercial platform, but the treatment remains experimental and the next clinical and regulatory steps are not dated here.
The read fails if later trials show weaker efficacy, unacceptable safety or dosing constraints, or regulators do not support the combination’s use.
CoverageSource: ZeroHedge · Published here THU, OCT 1 · 8:00 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Up to 23% average weight loss, 54 pounds lost at the highest dose and a 2.9-point A1C reduction could support a differentiated combination franchise alongside Lilly’s established Mounjaro business.
The evidence is limited to a reported 48-week experimental result in people with diabetes, leaving durability, safety, regulatory status and commercial uptake unresolved.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →